Oxford Biomedica (LON:OXB) Reaches New 1-Year Low at $198.20

Oxford Biomedica plc (LON:OXBGet Free Report) hit a new 52-week low on Friday . The stock traded as low as GBX 198.20 ($2.45) and last traded at GBX 199.40 ($2.46), with a volume of 165656 shares. The stock had previously closed at GBX 211 ($2.60).

Analysts Set New Price Targets

Separately, Liberum Capital decreased their target price on Oxford Biomedica from GBX 350 ($4.32) to GBX 310 ($3.83) and set a “hold” rating for the company in a report on Tuesday, September 26th.

View Our Latest Report on OXB

Oxford Biomedica Price Performance

The company has a debt-to-equity ratio of 57.10, a current ratio of 3.32 and a quick ratio of 1.67. The stock has a market cap of £192.98 million, a price-to-earnings ratio of -311.56 and a beta of 1.02. The stock has a fifty day moving average of GBX 262.86 and a 200 day moving average of GBX 363.01.

Insider Buying and Selling

In other news, insider Dame Kay Davies bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 26th. The stock was purchased at an average price of GBX 291 ($3.59) per share, with a total value of £2,910 ($3,592.15). In related news, insider Roch Doliveux purchased 36,130 shares of the firm’s stock in a transaction on Wednesday, September 20th. The stock was bought at an average cost of GBX 274 ($3.38) per share, with a total value of £98,996.20 ($122,202.44). Also, insider Dame Kay Davies purchased 1,000 shares of the firm’s stock in a transaction on Tuesday, September 26th. The stock was bought at an average cost of GBX 291 ($3.59) per share, with a total value of £2,910 ($3,592.15). Corporate insiders own 8.68% of the company’s stock.

Oxford Biomedica Company Profile

(Get Free Report)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.

Further Reading

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.